OS Therapies Inc. (OSTX) reported a fourth‑quarter and full‑year 2025 loss of $0.41 per share, falling short of the consensus estimate of a $0.16 loss per share and resulting in a miss of $0.25 per share. The company posted a net loss of $15.3 million for the nine months ended September 30, 2025, and a full‑year operating loss of $28.8 million, underscoring the continued cash burn typical of a clinical‑stage biopharma with no revenue yet.
The miss reflects the company’s heavy investment in regulatory submissions for its lead product, OST‑HER2, a targeted immunotherapy for osteosarcoma. With no product sales, the company’s operating expenses—primarily research and development, regulatory filing fees, and clinical trial costs—outpaced any incremental revenue, driving the quarterly loss. The magnitude of the miss is largely attributable to the absence of revenue and the scale of the regulatory investment required to advance OST‑HER2 toward a Biologics License Application (BLA) and a Marketing Authorization Application (MAA).
Regulatory progress for OST‑HER2 remains a key driver of analyst optimism. The product has received orphan drug designation, rare pediatric disease designation, and is positioned for accelerated approval. OS Therapies has submitted biomarker and clinical data packages to the FDA in preparation for a Pre‑BLA meeting and has held meetings with the MHRA and EMA to discuss regulatory pathways. The company’s pipeline also includes OST‑tADC, a tunable antibody‑drug conjugate platform, which supports future growth opportunities.
Funding risk is a critical concern. The company’s cash burn and lack of revenue create a “critical funding cliff” as it approaches key regulatory milestones. Auditors’ going‑concern paragraphs highlight the need for additional capital, and the company’s history of operating losses underscores its reliance on external financing. Investors and stakeholders are closely monitoring the company’s ability to secure new funding to sustain its regulatory and development activities.
Management emphasized the company’s focus on regulatory alignment and operational execution. Chairman & CEO Paul Romness highlighted the importance of OST‑HER2’s data and the company’s transformative period, while Chief Medical & Scientific Officer Robert Petit noted the submission of biomarker and clinical data packages to the FDA. These statements reinforce the company’s commitment to advancing its lead product and managing its cash position.
Looking ahead, OS Therapies plans to spin off its OS Animal Health subsidiary in the first half of 2026, which could streamline its focus on human therapeutics. The company remains optimistic about the potential for accelerated approval of OST‑HER2 and the monetization of a Priority Review Voucher, but it must secure additional capital to bridge the funding gap and maintain its regulatory trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.